GenMark Diagnostics (GenMark Diagnostics) Ending Cash Position : $42.2 Mil (As of Dec. 2020)

View and export this data going back to 2010. Start your Free Trial

What is GenMark Diagnostics Ending Cash Position?

GenMark Diagnostics's Ending Cash Position for the quarter that ended in Dec. 2020 was $42.2 Mil.

GenMark Diagnostics's quarterly Ending Cash Position declined from Jun. 2020 ($84.1 Mil) to Sep. 2020 ($59.5 Mil) and declined from Sep. 2020 ($59.5 Mil) to Dec. 2020 ($42.2 Mil).

GenMark Diagnostics's annual Ending Cash Position increased from Dec. 2018 ($37.0 Mil) to Dec. 2019 ($45.1 Mil) but then declined from Dec. 2019 ($45.1 Mil) to Dec. 2020 ($42.2 Mil).

GenMark Diagnostics Ending Cash Position Historical Data

The historical data trend for GenMark Diagnostics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GenMark Diagnostics Ending Cash Position Chart

GenMark Diagnostics Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Ending Cash Position

Get a 7-Day Free Trial

16.72

27.51

37.04

45.12

42.22

GenMark Diagnostics Quarterly Data
	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20
Ending Cash Position	Get a 7-Day Free Trial															45.12	27.02	84.07	59.46	42.22

GenMark Diagnostics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

GenMark Diagnostics's Ending Cash Position for the fiscal year that ended in Dec. 2020 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	45.118	+	-2.9
	=	42.2

GenMark Diagnostics's Ending Cash Position for the quarter that ended in Dec. 2020 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	59.455	+	-17.237
	=	42.2

GenMark Diagnostics Ending Cash Position Related Terms

Thank you for viewing the detailed overview of GenMark Diagnostics's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

GenMark Diagnostics (GenMark Diagnostics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » GenMark Diagnostics Inc (NAS:GNMK) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

N/A

Address

5964 La Place Court, Carlsbad, CA, USA, 92008-8829

Website

http://www.genmarkdx.com

GenMark Diagnostics Inc is a provider of automated, multiplex molecular diagnostic testing systems that detect and measure DNA and RNA targets to diagnose disease and optimize patient treatment. The company currently operates in one reportable business segment, which encompasses the development, manufacturing, sales, and support of instruments and molecular tests based on its proprietary eSensor detection technology. Its operations and assets are in the United States of America.

Executives

Tyler Jensen	officer: SVP, Engineering and Tech Dev	5964 LA PLACE COURT CARLSBAD CA 92008
Christine Shaw	officer: VP, Assay Development	5964 LA PLACE COURT CARLSBAD CA 92008
Alan Baer Maderazo	officer: VP, Qual, Reg, & Clin Affairs	5964 LA PLACE COURT CARLSBAD CA 92008
Michael Gleeson	officer: SVP, Corp. Accounts	5964 LA PLACE COURT, SUITE 100 CARLSBAD CA 92008
Sarah Hollis Winkler	officer: VP, Human Resources	5964 LA PLACE COURT CARLSBAD CA 92008
Michael John Harkins	officer: SVP, Sales	5964 LA PLACE COURT CARLSBAD CA 92008
John Frederick Ek	officer: Chief Financial Officer	5964 LA PLACE COURT, CARLSBAD CA 92008
Scott Mendel	director, officer: President & CEO	5964 LA PLACE COURT, ADDRESS 2, CARLSBAD CA 92008
Eric Stier	officer: SVP & General Counsel	5964 LA PLACE COURT CARLSBAD CA 92008
Brian Andrew Mitchell	officer: SVP, Operations	5964 LA PLACE COURT CARLSBAD CA 92008
Daryl Faulkner	director	5964 LA PLACE COURT, CARLSBAD CA 92008
Michael Kagnoff	director	DLA PIPER LLP (US) 4365 EXECUTIVE DRIVE, SUITE 1100 SAN DIEGO CA 92121
Lisa M. Giles	director	DURATA THERAPEUTICS, INC., 200 SOUTH WACKER DRIVE SUITE 2550, CHICAGO IL 60606
Kevin C Oboyle	director	5964 LA PLACE COURT, CARLSBAD CA 92008
James Fox	director	5964 LA PLACE COURT, CARLSBAD CA 92008